ATS 2020

The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.

Tobacco smoke exposure inhibited the therapeutic benefit of the cystic fibrosis transmembrane conductance regulator modulators in pediatric patients.

Compared with white patients, black patients with screen-detected cancers had a lower calculated lung cancer risk, despite having a significantly higher mean 6-year lung cancer risk.

Preemptive, patient-specific electronic messages from pulmonologists to primary care physicians improved guideline concordant care in COPD.

In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung function benefit compared with multiple-inhaler triple therapy.

Prenatal and early life exposure to household air pollution may affect the development of lung function and lead to an increase in airway resistance in children.

In terms of screening for obstructive sleep apnea in people living with HIV, the STOP-BANG questionnaire had good sensitivity, whereas the Berlin questionnaire and the Epworth Sleepiness Scale demonstrated good specificity.

BAY 1817080, a potent selective P2X3 receptor antagonist, may have utility as a new treatment for refractory chronic cough.

Approximately 1 in 4 current and former smokers with chronic obstructive pulmonary disease are at risk for mild cognitive impairment and dementia.

Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.